Crosstalk Between Thyroid Hormone Signaling and Β‐adrenergic Signaling in Myocardial Infarction

Kuo Zhang,Yida Tang,Youhua Zhang,Kaie Ojamaa,Amandeep Singh Saini,Maria Alicia Carrillo-Sepulveda,A. Martin Gerdes
DOI: https://doi.org/10.1096/fasebj.2018.32.1_supplement.717.27
2018-01-01
Abstract:BackgroundBeta blockers form one of the mainstay therapies for myocardial infarction (MI). Preclinical studies have shown efficacy and safety of thyroid hormone (TH) treatment of cardiovascular disorders. Although THs interact with the sympathoadrenal system at various levels, crosstalk between TH signaling and β‐adrenergic signaling remains poorly understood. We compared pathophysiologic and TH‐adrenergic signaling changes between therapeutic doses of triiodothyronine (T3) and metoprolol (Met) in rats with MI.MethodsFemale Sprague‐Dawley rats aged 12 weeks underwent left anterior descending coronary artery ligation (MI) or sham surgeries. T3 (5 μg/kg/d) or Met (100 mg/kg/d) were given in drinking water immediately after surgery for 8 weeks. At terminal experiments, rats were subjected to morphological, functional, and molecular examination.ResultsT3 and Met significantly enhanced left ventricular (LV) fractional shortening (LVFS 21.4±2.6% and 21.1±3.7%, respectively) compared to untreated MI (17.9±1.2%) and decreased the incidence of inducible atrial tachyarrhythmia by 87.5% and 62.5% without producing untoward effects. Although both treatments showed efficacy, T3 but not Met showed statistically significant improvements compared to MI in arrhythmia duration, left atrial diameter (T3 vs MI 4.3±0.6 vs. 5.7±1.3 mm, p<0.05; Met 4.9±1.1), fibrosis (6.1±0.6%, 6.6±0.6% vs. 8.2±0.7%, T3, Met vs. MI, respectively) and aortic vasorelaxation responsiveness (pD2 6.97±0.22, 6.83±0.21 vs. 6.66±0.22, T3, Met vs MI, respectively). Quantitative PCR showed that T3 and Met attenuated expression of genes associated with inflammation and oxidative stress and restored expression of ion channels and contractile proteins compared to MI rats. Importantly, thyroid and β‐adrenergic signaling genes were favorably regulated by both treatments.ConclusionThese results support comparable efficacy of long‐term treatment with a physiological dose of T3 that is comparable to Met and suggest a potential therapeutic alternative to standard β‐blockade for patients intolerant to treatment with β‐blockers after MI.Support or Funding InformationThis work was supported by the National Heart, Lung, and Blood Institute of the NIH, Bethesda, MD, under Award Number R01HL103671 (AG). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We also acknowledged the National Natural Science Foundation of China (No. 81470485), Capital Clinical Featured Application Research Project (NO. z151100004015175) and CAMS Innovation Fund for Medical Sciences (CIFMS 2016‐I2M‐1‐009).This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.
What problem does this paper attempt to address?